RIPK1 and systemic inflammatory response syndrome: In three inflammatory disease models (TNF-driven SIRS, colitis caused by NEMO deficiency in inflammatory bowel disease, and collagen antibody-induced arthritis), GNE684 played a protective role, suggesting that targeting RIPK1 was effective in treating inflammatory diseases.